Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-063 vs Copaxone in RRMS
NCT02753088Phase 3Completed
- Sponsor
- BIOCAD
- Start
- Oct 2013
- Primary completion
- Nov 2015
- Modality
- Peptides
01
Overview
Phase 3, randomised, double-blind trial of Timexon in relapsing-remitting multiple sclerosis (RRMS) (3 arms), sponsored by BIOCAD. Primary endpoint: Cumulative Unique Activity lesions at 48 weeks. Started Oct 2013; status: completed.
02
Drugs
Timexon
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT02753088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02753088.